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Previous studies in yeast and mammalian cells
showed a functional interaction between the
amino-terminal domain and the carboxy-terminal,
ligand-binding domain (LBD) of the human andro-
gen receptor (AR). In the present study, the AR
subdomains involved in this in vivo interaction
were determined in more detail. Cotransfection ex-
periments in Chinese hamster ovary (CHO) cells
and two-hybrid experiments in yeast revealed that
two regions in the NH2-terminal domain are in-
volved in the functional interaction with the LBD:
an interacting domain at the very NH2 terminus,
located between amino acid residues 3 and 36, and
a second domain, essential for transactivation, lo-
cated between residues 370 and 494. Substitution
of glutamic acid by glutamine at position 888
(E888Q) in the AF-2 activation domain (AD) core
region in the LBD, markedly decreased the inter-
action with the NH2-terminal domain. This muta-
tion neither influenced hormone binding nor LBD
homodimerization, suggesting a role of the AF-2
AD core region in the functional interaction be-
tween the NH2-terminal domain and the LBD. The
AF-2 AD core region was also involved in the inter-
action with the coactivator TIF2 (transcriptional in-
termediary factor 2), as the E888Q mutation de-
creased the stimulatory effect of TIF2 on AR AF-2
activity. Cotransfection of TIF2 and the AR NH2-
terminal domain expression vectors did not result
in synergy between both factors in the induction of
AR AF-2 activity. TIF2 highly induced AR AF-2 ac-
tivity on a complex promoter [mouse mammary
tumor virus (MMTV)], but it was hardly active on a
minimal promoter (GRE-TATA). In contrast, the AR
NH2-terminal domain induced AR AF-2 activity on
both promoter constructs. These data indicate that
both the AR NH2-terminal domain and the coacti-
vator TIF2 functionally interact, either directly or
indirectly, with the AF-2 AD core region in the AR-
LBD, but the level of transcriptional response in-
duced by TIF2 depends on the promoter context.
(Molecular Endocrinology 12: 1172–1183, 1998)
INTRODUCTION
The human androgen receptor (hAR) mediates physi-
ological effects of testosterone and dihydrotestoster-
one (DHT), which are essential for development and
functional maintenance of male reproductive and ac-
cessory sex tissues. As a ligand-dependent transcrip-
tion factor, its structural organization shows a high
level of molecular identity to other members of the
nuclear receptor superfamily. For these receptors,
separate functional domains have been characterized.
The variable NH2-terminal domain is involved in tran-
scription activation and contains the transactivation
function AF-1 (see Ref. 1 for review). The centrally
located, highly conserved DNA-binding domain (DBD)
mediates the interaction with hormone-response ele-
ments on the DNA (2). The carboxy-terminal (C-termi-
nal) region contains the ligand binding domain (LBD),
which is involved in receptor dimerization (3–6), and
can functionally interact with transcriptional interme-
diary factors (TIFs) (for review see Ref. 7).
For the hAR, two separate transcription activation
units (TAUs) in the NH2-terminal domain were defined
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(8). One of these transactivation units [TAU-1; amino
acids (aa) 100–370] is only active in the full-length
ligand-activated AR. In a truncated hAR, which lacks
the LBD, another region (TAU-5, aa 360–485) func-
tions as a constitutively active transactivation domain.
The role of TAU-5 in the full-length AR is not yet clear.
The LBDs of various nuclear receptors contain a
ligand-dependent transactivation function, AF-2 (9–
11). An autonomous activating domain (AD) in this
AF-2 region, AF-2 AD, is conserved among many nu-
clear receptors and is located in the C-terminal part of
the LBD. A core region in the AF-2 AD, a-helix 12,
appeared to be important for transcriptional activity (9,
10, 12, 13) and the hormone-dependent interaction
with TIFs. These TIFs or coactivators can modulate the
transcriptional activity of a broad range of nuclear
receptors (14–17). Mutations in the AF-2 AD core abol-
ish the in vitro association of the receptor with these
coactivators. The recent finding that a coactivator dis-
plays histone acetyltransferase activity has provided
further insights into the molecular events occurring at
the chromatin level during transcription activation (18).
Wurtz et al. (19) proposed a general mechanism for
nuclear receptor activation, in which the AF-2 AD core,
present in helix 12, plays a central role in the genera-
tion of an interaction surface, allowing binding of TIFs
to the LBD. The functional role of the AF-2 AD core in
the AR is not yet well understood.
Recently, for the estrogen receptor (ER) a functional,
ligand-dependent, in vivo association between the
NH2-terminal domain and the LBD was described (20).
Also for the AR a functional in vivo interaction between
the NH2-terminal domain and the LBD was demon-
strated (21, 22). In the study presented here, we de-
termined in more detail AR subdomains involved in the
functional interaction of the LBD with the NH2-terminal
domain. The data indicated that two NH2-terminal re-
gions, together with the AF-2 AD core region in the
LBD, are important for a functional in vivo interaction.
Induction of AR AF-2 activity by the transcriptional
coactivator TIF2 also required an intact AF-2 AD core.
This enhancement of AR AF-2 activity by TIF2 ap-
peared to be promoter dependent.
RESULTS
Two Regions in the AR NH2-Terminal Domain Are
Involved in the Functional Interaction with the
AR-LBD
Studies in CHO Cells A functional in vivo associa-
tion between the NH2-terminal domain and LBD of the
hAR was found previously (22). Experiments per-
formed in yeast and mammalian cells showed that this
interaction was hormone dependent and could be
blocked by antiandrogens. The present study focused
on AR subdomains involved in this NH2-terminal
domain/LBD protein-protein interaction.
To determine regions in the NH2-terminal domain
involved in the functional interaction with the AR-LBD,
different deletion mutants of the NH2-terminal domain
were constructed, as shown in Fig. 1A (AR.N1-AR.N7).
The deletion mutants were transiently transfected into
CHO cells, and the appropriate expression of the pro-
teins was assessed by immunoaffinity purification and
Western blot analysis of cytosolic fractions (Fig. 1B,
lanes 1–7). Constructs (AR.N1- AR.N6) were ex-
pressed as proteins of expected molecular mass and
at comparable expression levels. The expression level
of AR.N7 could not be determined because this pro-
tein lacks an epitope for the available antibodies.
The ability of these mutants to induce transcription
activation through interaction with the AR-LBD (Fig.
1A; AR.C), using mouse mammary tumor virus
(MMTV)-LUC as a reporter gene, is shown in Fig. 2. As
shown previously (22), neither AR.N1 nor AR.C could,
when expressed separately in CHO cells, activate
transcription from the reporter in response to andro-
gens. The lack of activity of AR.C is not due to the
experimental setup, because a similar glucocorticoid
receptor (GR) fragment, GR.C (aa 369–777), highly
induced luciferase activity in CHO cells (24-fold) upon
addition of 10 nM dexamethasone (data not shown).
Coexpression of AR.N1 and AR.C resulted in an an-
drogen-dependent induction (18-fold) of luciferase ex-
pression (Fig. 2; AR.N1), which is comparable to full-
length AR activity. Deletion mutants AR.N2 and AR.N3
showed similar responses as seen with the intact NH2-
terminal domain. However, deletion of amino acid res-
idues 371–494 markedly reduced the androgen-
induced LUC-activity (AR.N4). Deletions in the first
part of the NH2-terminal domain (AR.N5, AR.N6,
AR.N7) almost completely abolished the R1881-medi-
ated response. These data indicate that, for a func-
tional interaction of the NH2-terminal domain with the
LBD of the AR in CHO cells, amino acid residues 1–51
and 371–494 are important. This suggests that the
TAU-5 domain, located in the latter region, is involved
in this functional in vivo interaction. The region be-
tween residues 51 and 360, harboring TAU-1, appears
not to be involved.
Studies in Yeast To extend the CHO cell experi-
ments, functional NH2-terminal domain/LBD interac-
tions were studied in yeast, using a two-hybrid sys-
tem. The high sensitivity of the yeast two-hybrid assay
made it also possible to detect weak associations.
Furthermore, because of the presence of the Gal4
transactivation domain, the in vivo interaction does not
solely depend on an intact AR-transactivating domain.
Truncated forms of the AR NH2-terminal domain
were fused to the transactivation domain of GAL4
(Gal4-TAD), in the high-expression vector pACT2 (Fig.
3A). AR-LBD was fused to the DBD of GAL4 (Gal4-
DBD). Figure 3B shows the protein expression in yeast
Y190 cells, as assessed by immunoblot analysis using
specific antibodies directed against either the AR
(lanes 1–4) or Gal4-TAD (lanes 5–10). The immunoblot
shows expression of most fusion proteins of the ap-
propriate length. However, the expression of GalAD-
Interaction of hAR AF-2 with NH2 Terminus and TIF2 1173
 at Medical Library Erasmus MC on December 11, 2006 mend.endojournals.orgDownloaded from 
AR.N9 (lane 2) appeared to be somewhat lower. Ga-
lAD-AR.N8 became visible only at an extended
exposure time (lane 1a), indicating a very low protein
expression level.
Activation of the integrated UASGAL1-lacZ reporter
gene, indicative for the functional interaction of GalAD-
AR.N with the promoter-bound GalDBD-AR.C, was
assessed in a b-galactosidase (b-GAL) assay (Fig. 4A).
The observed reporter gene activity for GalAD-AR.N8
was lower as compared with GalAD-AR.N9, GalAD-
AR.N10, and GalAD-AR.N12, most likely due to the
very low protein expression level of GalAD-AR.N8. The
constructs showing a high b-GAL activity (GalAD-
AR.N8, -N9, -N10, and -N12) all share one common
region, spanning residues 3–36. Deletion of this region
from constructs GalAD-AR.N12 and GalAD-AR.N15,
resulting in constructs GalAD-AR.N13 and GalAD-
AR.N16, respectively, caused an intense drop in
b-GAL activity. Therefore, in accordance with the CHO
results, the data imply an important role of NH2-termi-
nal amino acid residues 3–36 in the functional inter-
action with the AR-LBD.
Mutant GalAD-AR.N11, missing residues 245–494,
was reduced in its activity as compared with the intact
NH2-terminal domain. A decrease in activity was also
seen when residues 330–494 were deleted from
Fig. 1. Structure and Protein Expression Patterns of AR Mutants Used in the Transfection Studies in CHO Cells
A, The full-length hAR is shown with its NH2-terminal domain (N-TERM), DBD, and LBD. The total number of amino acid
residues in the full-length hAR is 910 and is based on amino acid stretches of 20 Gln and 16 Gly residues. Synthetic peptide
sequences in the AR to which antibodies were raised and that were used in this study are depicted (SP). The various NH2-terminal
constructs (AR.N1 to AR.N7) and C-terminal constructs [AR.C and AR.C(EQ)] are shown. B, The AR proteins were expressed in
CHO cells and immunopurified from cytosolic fractions, as described in Materials and Methods. The proteins were visualized by
immunoblotting with polyclonal antibodies against SP197 (lanes 1–4), SP061 (lanes 5–7), or SP066 (lanes 8–10). The molecular
mass marker values are indicated on the left of each blot.
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GalAD-AR.N12, resulting in GalAD-AR.N15. This im-
plies that a second region, between residues 244 and
494, is involved in the functional interaction with the
LBD. More detailed mapping within this region did not
clearly reveal distinctive interaction sites, because nei-
ther deletion of residues 245–360 (GalAD-AR.N9), nor
deletion of residues 371–494 (GalAD-AR.N10), re-
sulted in a distinct decrease of b-GAL activity. How-
ever, interpretation of these data is complicated be-
cause of the difference in expression levels of the
different constructs (Fig. 3B).
As reported previously (22), the measured b-GAL
activities are partly due to Gal4-TAD transactivity, but
could also be influenced by the intrinsic transactivat-
ing activity of the AR NH2-terminal domain. The con-
tribution of the intrinsic AR activity to the total mea-
sured b-GAL activity could vary between different
constructs and thereby affect the mapping of interact-
ing regions. To discriminate between AR transactivity
and AR interaction potential, the Gal4-TAD part was
deleted from these GalAD-AR.N constructs that
showed a considerable interaction with GalDBD-AR.C
(as depicted in Fig. 4A). This resulted in constructs
AR.N8-AR.N12 and AR.N15. Protein expression of
these constructs, as determined by immunoblot anal-
ysis, is shown in Fig. 3B (lanes 11–16).
The activities of the AR.N constructs, in the two-
hybrid assay with GalDBD-AR.C, are shown in Fig. 4B.
AR.N11 and AR.N15 did not induce a functional inter-
action, although the corresponding Gal4-TAD chi-
meric constructs, as shown in Fig. 4A, were active.
This indicates that AR.N11 and AR.N15 only contain
interaction potential and not transactivity. These con-
structs have the 3–36 fragment in common. Deletion of
the region between residues 244 and 360 (AR.N9) did
not reduce b-GAL activity; AR.N12 (missing residues
37–243) also showed a clear response. This indicates
that both these proteins still have transactivating ac-
tivity and interaction potential. However, by deleting
residues 371–494 (AR.N10), b-GAL activity dropped
by approximately 80%, a decrease comparable to the
data obtained in CHO cells (Fig. 2; AR.N4). These
results narrow the second interacting region (aa 244–
494) to involvement of residues 371–494 as a major
transactivation domain in the functional interaction
with the LBD.
Taken together, the yeast two-hybrid data imply a
prominent role of amino acid residues 3–36 of the AR
NH2-terminal domain in the interaction with the LBD. A
second region seems to be mainly constrained to res-
idues 371–494 and further supports the involvement of
TAU-5, as a transactivating region, in the functional in
vivo interaction with the LBD.
A Mutation in the LBD Affects the Functional
Interaction with the NH2-Terminal Domain, but
not LBD Dimerization
To determine regions in the AR-LBD involved in the
functional interaction with the NH2-terminal domain,
mutational analysis was constrained to the conserved
amphipathic helix 12 in the LBD. This helix constitutes
the AF-2 activation domain (AD) core region, of which
the charged residues might generate a protein-protein
interacting surface (19). A single amino acid substitu-
tion in the AF-2 AD core was introduced: glutamic acid
at position 888, which is highly conserved among nu-
clear receptors, was replaced by glutamine (E888Q).
Both the wild-type and the mutated LBD construct
(Fig. 1A; AR.C and AR.C(EQ), respectively) were trans-
fected into CHO cells. The appropriate expression of
both proteins is shown in Fig. 1B (lanes 8 and 9). To
determine whether the AF-2 AD mutation had an effect
on hormone binding, an in vivo androgen binding as-
say in transfected CHO cells was performed. Scat-
chard analysis of the data revealed that both proteins
had similar Kd values for R1881: AR.C, 0.37 nM, and
AR.C(EQ), 0.33 nM, respectively, indicating that the
E888Q mutation did not affect hormone binding.
The effect of the E888Q mutation on the functional in
vivo interaction of the LBD with the NH2-terminal do-
main was investigated by cotransfecting AR.N1 with
increasing amounts of either AR.C or AR.C(EQ) and
the MMTV-LUC reporter into CHO cells (Fig. 5A). As
expected, no response to 1 nM R1881 was observed in
the absence of the LBD constructs. Coexpression of
AR.C and AR.N1 resulted in a high induction (to 24-
fold) of luciferase activity. The E888Q mutation
Fig. 2. Transcriptional Activities of AR NH2-Terminal Dele-
tion Mutants Cotransfected with AR.C in CHO Cells
Transcriptional activities were determined by transfecting
full-length AR (3 ng/well) or by cotransfection of AR.C (50
ng/well) with each of the NH2-terminal constructs (100 ng/
well), together with a MMTV-LUC reporter plasmid (200 ng/
well), into CHO cells. Cells were incubated either with vehicle
(open bars) or with 10 nM R1881 (closed bars). Luciferase
activity was determined as described in Materials and Meth-
ods. The interexperimental variation of the mean maximal
luciferase activities ranged between 2,000 and 9,000 light
units. For each experiment the mean AR.N1 activity was set
at 100%, and all individual points were calculated relative to
this value. Each bar represents the mean (6 SEM) luciferase
activity for three experiments. Fold induction is shown at the
top of each bar and represents the ratio of activity determined
in the presence or absence of R1881.
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strongly reduced the response to R1881 (to maximally
a 7-fold induction) as compared with the wild-type
LBD.
The effect of the E888Q mutation on the functional
interaction between the two AR domains was also
studied in yeast, using the two-hybrid system. Both
C-terminal domains (wild-type and mutant), fused to
Gal4-DBD, were transformed together with GalAD-
AR.N8 into Y190 (Fig. 5B; NH2/LBD). The effect of
the E888Q mutation appeared to be even more pro-
nounced than in CHO cells, as b-GAL activity mea-
sured for the interaction of both AR domains (set at
100% for the intact LBD) dropped more than 90%
upon introduction of the E888Q mutation. The data
from CHO cells and from yeast indicate that the
AF-2 AD core region in the AR-LBD is important for
a functional interaction with the NH2-terminal
domain.
Previously, homodimerization of the AR-LBD was
demonstrated in yeast (22, 23). To determine whether
the E888Q mutation had an effect on LBD dimeriza-
tion, both LBDs (wild-type and mutant) were coupled
to Gal4-TAD and transformed together with the corre-
sponding LBD domains coupled to Gal4-DBD (Fig.
5C). In this LBD/LBD interaction assay, the wild-type
AR.C and the mutant AR.C(EQ) showed similar b-GAL
levels, indicating that the E888Q mutation had no ef-
fect on LBD dimerization.
Fig. 3. Structure and Expression Patterns of AR-Gal4 Fusion Proteins Used in the Two-Hybrid Studies in Yeast
A, Shown are AR NH2-terminal mutants fused to the Gal4 transactivating domain (TAD) and the LBD fused to the Gal4 DBD.
B, The appropriate expression of the AR constructs in yeast was determined by immunoblotting of lysates of transformed S.
cerevisiae Y190 cells with specific antibodies against the AR (SP197, lanes 1–4 and lanes 11–16) or against Gal4-TAD (lanes 5–10).
Lane 1a represents GalAD-AR.N8 at a 5-fold longer exposure time of the immunoblot during chemiluminescence detection. The
molecular mass marker values are indicated on the left side of each blot.
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TIF2-Induced Activity of AR AF-2 in CHO Cells Is
Affected by the E888Q Mutation
The functional role of the AR AF-2 AD core region was
further characterized by comparing the functional
in vivo interaction of the AR-LBD and the AR NH2-
terminal domain with the interaction of the AR-LBD
and the coactivator TIF2. The coactivator TIF2 is able
to enhance the AF-2 activity of several steroid recep-
tors including the AR (17). The involvement of the AR
AF-2 AD core region in the functional in vivo interaction
of TIF2 and the AR-LBD was investigated by examin-
ing the effect of the E888Q mutation.
TIF2 was cotransfected with the MMTV-LUC re-
porter and increasing amounts of the wild-type (AR.C)
or the mutant LBD (AR.C(EQ)) into CHO cells (Fig. 6).
In the absence of the LBD constructs, no response to
1 nM R1881 was observed. As expected, coexpression
of TIF2 and AR.C highly induced luciferase activity (up
to 26-fold). The E888Q mutation reduced luciferase
activity by approximately 70%, compared with AR.C.
This decrease in functional interaction of AR-LBD with
TIF2, caused by the E888Q mutation, was comparable
to the negative effect of the mutation on the interaction
with the NH2-terminal domain (as shown in Fig. 5A).
TIF2 Does Not Promote the Functional
Interaction between the AR NH2-Terminal
Domain and the LBD
To determine whether TIF2 enhances the functional
interaction between the NH2-terminal and C-terminal
domains of the AR, coexpression studies with different
concentrations of TIF2 and the NH2-terminal domain
were performed (Fig. 7). The luciferase activities ob-
tained were compared with the transactivating activi-
ties measured after separate transfection of the differ-
ent plasmids. Individual expression of TIF2 and the
NH2-terminal domain induced the transcriptional ac-
tivity of AR.C on the MMTV promoter up to 24-fold
(panels a and d, respectively). When coexpressed with
50 ng/well AR.N1 (panel b), TIF2 slightly enhanced the
luciferase activity induced by the functional interaction
of AR.N1 and AR.C (up to 34-fold). When higher
amounts of AR.N1 were transfected, no additional ef-
fects of TIF2 could be observed (panels c and d).
These data most likely exclude synergy between TIF2
and the NH2-terminal domain for the interaction with
the AR-LBD, indicating that TIF2 is not necessary for
the functional interaction between the AR domains.
TIF2-Induced Activity of AR AF-2 in CHO Cells Is
Promoter Dependent
To further examine the induction of AR AF-2 activity by
the NH2-terminal domain and by TIF2, in vivo interac-
tion assays in CHO cells were performed using differ-
ent promoter constructs (Fig. 8). AR.C was cotrans-
fected into CHO cells with increasing amounts of
either AR.N1 (Fig. 8, A and C) or TIF2 (Fig. 8, B and D),
together with either MMTV-LUC (Fig. 8, A and B) or
GRE-TATA-LUC (Fig. 8, C and D) as reporter con-
structs. In the absence of either AR.N1 or TIF2, no
significant response to 1 nM R1881 could be detected.
AR.N1 as well as TIF2 induced AF-2 activity on the
MMTV-LUC promoter (maximally 39- and 44-fold, re-
spectively). Luciferase activity was also highly induced
by AR N.1 on the minimal, GRE-TATA, promoter (Fig.
8C). In contrast, the TIF2-induced luciferase activity
appeared to be much more affected on this promoter
(Fig. 8D). This indicates that the level of transcriptional
Fig. 4. Two-Hybrid Assay of AR NH2-Terminal Deletion Mu-
tants and GalDBD-AR.C in Yeast
Yeast Y190 cells, containing the integrated UASGal1-lacZ
reporter gene, were transformed with the expression plasmid
GalDBD-AR.C, together with each of the Gal4-TAD fusion
proteins (GalAD-AR.N8 to GalAD-AR.N16) (A), or with the AR
proteins without the Gal4-TAD part (AR.N8 to AR.N12 and
AR.N15) (B). b-GAL activity was determined after incubation
of the cells in the absence (open bars, not visible) or presence
(solid bars) of 1 mM DHT. Fold induction is shown at the top
of each bar and represents the ratio of activity determined in
the presence and absence of DHT. b-GAL values represent
the mean (6SEM) of three experiments.
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response induced by TIF2 depends on the promoter
context.
DISCUSSION
Upon hormone binding, steroid receptors undergo
conformational changes that result in a cascade of
events leading toward DNA binding and transcription
activation. Protein-protein interactions play a promi-
nent role in these processes. After releasing associ-
ated heatshock proteins, the receptor homodimerizes,
and subsequently interacts with TIFs and basal tran-
scription factors, to induce transcription of specific
target genes (3–7). For the hAR, two separate tran-
scription activation units in the NH2-terminal domain
were defined: TAU-1 and TAU-5 (8). TAU-1 is active in
the full-length, hormone-bound AR, whereas TAU-5 is
active in a constitutive receptor that lacks the LBD.
This shift in TAU in the NH2-terminal domain, depend-
ing on the absence or presence of the LBD, suggested
a functional interaction between the LBD and the NH2-
terminal domain.
It was described recently, for the ER and AR, that
functional in vivo interactions between the separate
NH2-terminal domain and the LBD can occur (20–22).
Whether this association is direct or requires addi-
tional factors is unknown. Neither is it clear which
regions in these AR domains are involved in this func-
tional interaction. For a better understanding of AR
action, we determined the subdomains in the AR in-
volved in the functional interaction between the NH2-
terminal domain and the LBD.
Cotransfection experiments of the AR-LBD with
NH2-terminal deletion mutants in CHO cells and in
yeast imply a major role for amino acid residues 3–36
of the NH2-terminal domain in the functional in vivo
interaction with the LBD. A previous report by Langley
et al. (21) indicated residues 14–150 to be involved,
suggesting that the interaction domain might be con-
strained to residues 14–36. In this respect it is inter-
esting that region 16–36 is potentially capable of form-
ing an amphipathic a-helix, if projected on a helical
wheel diagram.
Experiments in CHO cells revealed a second region,
amino acid residues 371–494, important for a func-
tional in vivo interaction with the AR-LBD. The involve-
GalDBD-AR.C(EQ). b-GAL activity was determined after in-
cubation of the cells in the absence (open bars) or presence
(solid bars) of 1 mM DHT. Fold induction represents the ratio
of activity determined in the presence and absence of DHT.
b-GAL values represent the mean (6SEM) of three experi-
ments. C, Yeast Y190 cells, containing the integrated UAS-
Gal1-lacZ reporter gene, were transformed with GalDBD-AR.C
(low) and GalAD-AR.C (high) or GalDBD-AR.C(EQ) (low) and
GalAD-AR.C(EQ) (high). b-GAL activity was determined as
described in panel B.
Fig. 5. Differential Effects of the AF-2 AD Core Mutation
E888Q on Functional in Vivo NH2-Terminal Domain/LBD and
LBD/LBD Interactions
A, CHO cells were transfected with AR.N1 (100 ng/well)
and increasing amounts of AR.C or AR.C(EQ) together with
the MMTV-LUC reporter plasmid. Cells were incubated with
vehicle (open bars) or 1 nM R1881 (solid bars). LUC activity
was determined as described in Materials and Methods. The
interexperimental variation of the mean maximal luciferase
activities ranged between 8,000 and 13,000 light units. For
each experiment the mean AR.C activity (5 ng/well) was set at
100%, and all individual points were calculated relatively to
this value. Each bar represents the mean (6SEM) luciferase
activity for three experiments. Fold induction represents the
ratio of activity determined in the presence and absence of
R1881. B, Yeast Y190 cells, containing the integrated UAS-
Gal1-lacZ reporter gene, were transformed with the expres-
sion plasmid GalAD-AR.N8 together with GalDBD-AR.C or
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ment of this NH2-terminal region was confirmed by
data obtained with the two-hybrid system in yeast.
This region harbors TAU-5 (8), postulating a role for
this transcription activation unit in the functional inter-
action with the LBD. A recent report by McEwan and
Gustafsson (24) described the interaction of the AR
NH2-terminal domain (aa 142–485) with the general
transcription factor TFIIF. It remained unclear which of
the transactivation units (TAU-1 or TAU-5) in the AR
NH2-terminal domain is involved in the interaction with
TFIIF, as both TAUs are present in the AR domain used
in this study. Therefore, the role of TAU-5 in the inter-
action with the AR-LBD might be, at least in part, by
recruiting the transcriptional machinery to the target
promoter.
The in vivo experiments described here imply an
important role for the AR AF-2 AD core in the func-
tional interaction with the NH2-terminal domain. The
E888Q mutation markedly decreased the interaction
between the two AR domains, without altering hor-
mone binding. As the E888Q mutation did not com-
pletely reduce the interaction, it is likely that also other
residues or regions in the LBD are involved in the
formation of a proper interacting surface. Wurtz et al.
(19) proposed a general mechanism for nuclear recep-
tor activation, in which hormone-induced conforma-
tional changes within the LBD result in a close contact
of helix 12 and helix 4, thereby creating an interaction
surface that allows binding of coactivators to the AF-2
activation domain. As the formation of this interaction
surface might also be important for the functional in-
teraction of the LBD with the NH2-terminal domain,
this would suggest that helix 4 is involved. Two-hybrid
experiments in yeast showed that the E888Q mutation
affected the functional interaction with the NH2-
terminal domain but did not influence LBD ho-
modimerization. This implies that different regions in
the AR-LBD are involved in the interaction with the
NH2-terminal domain and in LBD dimerization.
The E888Q mutation also decreased the stimulatory
effect of the coactivator TIF2 on AR AF-2 activity. This
suggests that the AF-2 AD core region of the hAR is
involved in interacting with both the NH2-terminal do-
main and the coactivator TIF2. A possible mechanism
of TIF2 action could be as a bridging factor in the
process of transcription activation by the AR. McIner-
ney et al. (25) demonstrated that the steroid receptor
coactivator SRC-1 enhanced the functional interaction
between the NH2-terminal and C-terminal domain of
the ER. From these data it was suggested that SRC-1
may act as an adaptor protein that promotes the in-
Fig. 6. E888Q Mutation Affects TIF2-Enhanced Activation of
AR.C in CHO Cells
TIF2 (100 ng/well) was cotransfected into CHO cells with
increasing amounts of AR.C or AR.C(EQ) and MMTV-LUC as
a reporter. Cells were incubated with vehicle (open bars) or 1
nM R1881 (solid bars). LUC activity was determined as de-
scribed in Materials and Methods. The interexperimental vari-
ation of the mean maximal luciferase activities ranged be-
tween 2,800 and 5,900 light units. For each experiment the
mean AR.C activity (15 ng/well) was set at 100%, and all
individual points were calculated relative to this value. Each
bar represents the mean (6SEM) luciferase activity of three
experiments. Fold induction represents the ratio of activity
determined in the presence and absence of R1881.
Fig. 7. The Effect of Cotransfecting TIF2 on the Functional
Interaction of AR.N1 and AR.C
CHO cells were transfected with AR.C (25 ng/well) together
with increasing amounts of either TIF2 (50–400 ng/well, panel
a) or AR.N1 (50–400 ng/well, represented by 2 in panels b–d;)
and with combinations of both (panels b, c, and d). MMTV-
LUC was used as a reporter. Cells were incubated with
vehicle (open bars) or 1 nM R1881 (solid bars). LUC activity
was determined as described in Materials and Methods. The
interexperimental variation of the mean maximal luciferase
activities ranged between 120,000 and 375,000 light units.
For each experiment the mean AR.N1 activity (400 ng/well)
was set at 100%, and all individual points were calculated
relative to this value. Each bar represents the mean (6SEM)
luciferase activity of three experiments. Fold induction rep-
resents the ratio of activity determined in the presence and
absence of R1881.
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tegration of NH2-terminal and C-terminal ER domains.
However, cotransfection experiments with TIF2 and
the AR NH2-terminal domain in CHO cells did not
show synergy between TIF2 and the AR NH2-terminal
domain in the induction of AR AF-2 activity (Fig. 7).
Therefore, it is unlikely that TIF2 functions as a bridg-
ing factor for the functional interaction of the NH2-
terminal domain and the LBD of the AR.
The AR appears to be a unique member in the
nuclear receptor superfamily, because the AR C-
terminal domain, containing the AF-2 AD core region,
is inactive in the absence of the NH2-terminal domain
or TIF2. This lack of activity is not due to the experi-
mental setup or the cell type used (CHO), because a
similar C-terminal construct of the GR is active. The
most likely explanation of this difference is that inter-
actions of the AR-AF2 AD with endogenous coactiva-
tors are very weak and therefore undetectable. Over-
expression of coactivators (e.g. TIF2) might enhance
the interaction and consequently transcriptional activ-
ity. Another explanation for the absence of AR AF-2
activity in CHO cells is that endogenous levels of TIF2
are not sufficient for activation of the MMTV promoter
in the absence of AR.N1.
A signature motif in transcriptional coactivators that
mediated binding to liganded nuclear receptors was
described recently (26–28). Most coactivators, includ-
ing TIF2, harbor several of these leucine-rich motifs
(LXXLL). Two-hybrid experiments in yeast revealed
that the interaction of the ER-LBD with LXXLL motifs
was abolished by mutating the AF-2 AD core region in
the LBD (26). Despite the demonstration that the NH2-
terminal domain of the AR also interacts with the AF-2
AD, it does not harbor such a motif, suggesting a
different type of cooperation between the two AR
domains.
The induction of AF-2 activity by TIF2 appeared to
be promoter dependent. TIF2 strongly stimulated AR
AF-2 activity on a MMTV-LUC reporter but much less
on a minimal GRE-TATA promoter. The AR NH2-
terminal domain could, in contrast to TIF2, induce
AF-2 activity on both promoters. Possibly, TIF2 not
only affects the AR but also interacts with other tran-
scription factors that bind to the complex MMTV
promoter and not to the minimal promoter.
From the data presented here, together with previ-
ously obtained results (22), the following model for
functional interactions between AR domains is pro-
posed. Androgen binding induces a conformational
change in the receptor that facilitates the AF-2 AD core
in the LBD to interact with the NH2-terminal domain.
This interaction might be either direct or indirect, re-
quiring additional factors, and results in AR transcrip-
tion activation. Enhancement of AR activity by the
coactivator TIF2 also involves the AF-2 AD core. In
addition to a functional NH2-terminal domain/LBD in-
teraction, a LBD/LBD interaction is proposed that re-
quires a region different from the AF-2 AD core.
MATERIALS AND METHODS
Plasmid Construction
Plasmid constructions were performed according to stan-
dard methods (29) and where denoted, rendered blunt ended
with Klenow. All blunt-ended fusion constructs, and con-
structs including a PCR amplification step for preparation,
were sequenced to verify the correct reading frame and the
absence of random mutations. AR.N1 and AR.C were de-
scribed previously as pSVAR(TAD12494)(22) and pSVAR-104
(8), respectively. AR.N2, AR.N3, AR.N5, AR.N6, and AR.N7
were obtained by modification of AR D 51–211 and AR D
244–360 (30), AR124, AR127, and AR106 (8) respectively :
plasmids were digested with KpnI and EcoRI and religated by
a KpnI-EcoRI linker. AR.N4 was obtained by insertion of a
RsrII-EcoRI linker into AR.N1. pSVAR(EQ) was constructed
by site-directed mutagenesis of pSVAR (31), using the fol-
lowing oligonucleotides (the modified codon is shown
underlined):
AR/EQ1: 59-ACAGCCAGTGTGTCCGAATG-39;
AR/EQ2: 59-CTTGCACAGAGATGATTTGTGCCATC-39;
AR/EQ3: 59-GATGGCACAAATCATCTCTGTGCAAG-39;
AR/EQ4: 59-CAAGGGGCTTCATGATGTCC-39.
AR.C(EQ) was prepared by digestion of pSVAR(EQ) with
EcoRI and ligating the 465-bp fragment into AR.C. MMTV-
LUC reporter plasmid was kindly provided by Dr. Dijkema
(Organon, Oss, The Netherlands) and was described previ-
ously (32). GRE-TATA-LUC, containing the TATA-box and a
Sp1-site derived from the Oct-6 gene promoter, has been
described previously as pJH4-(ARE)2-OCT-LUC (33). GR.C
(aa 369–777) was constructed by digestion of RshGRa (34)
Fig. 8. Enhancement of the Transcriptional Response by
TIF2 in CHO Cells Is Promoter-Dependent
CHO cells were transfected with AR.C (50 ng/well) and
increasing amounts of AR.N1 (panels A and C) or TIF2 (panels
B and D) together with the reporter plasmids MMTV-LUC
(panels A and B) or GRE-TATA-LUC (panels C and D). Cells
were incubated with vehicle (open bars) or 1 nM R1881 (solid
bars). LUC activity was determined as described in Materials
and Methods. The interexperimental variation of the mean
maximal luciferase activities ranged between 4,800 and
6,400 light units for panels A and B, and between 11,500 and
13,500 light units for panels C and D. For each experiment the
mean AR.N1 activity (1000 ng/well) was set at 100%, and all
individual points were calculated relative to this value. Each
bar represents the mean (6SEM) luciferase activity of three
experiments. Fold induction represents the ratio of activity
determined in the presence and absence of R1881.
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with BstXI and religation with a compatible DNA fragment
obtained by annealing the following oligos: 59-AGCCCGG-
GACCATGGGAT-39 and 59-CATGGTCCCGGGCTATCC-39.
The obtained plasmid was digested with SmaI and DraI, and
the 1074-bp fragment, containing the GR DBD and LBD, was
ligated into SmaI-digested pSV328A (35).
The GAL4(DBD12147) two-hybrid cloning vector pGBT9
and the parental GAL4(TAD7682881) cloning vector pGAD424
(low expression), or the high-level expression derivative
pACT2 (all from Clontech, Palo Alto, CA), were used to gen-
erate all yeast fusion protein constructs. GalAD-AR.N8 (low)
was described previously as pGAL4(TAD)AR(TAD) (22). Ga-
lAD-AR.N11 (low) was generated by digesting GalAD-AR.N8
(low) with NcoI and SalI, followed by religation of the blunted
vector. The previously described pTZ19NAR (22), containing
an additional BamHI site by addition of a BamHI linker to the
blunt-ended EcoRI site in the polylinker, was digested with
SmaI and NcoI, and the resulting vector was blunt ended and
religated, yielding pTZ19AR.N12. The AR fragment was ex-
cised with BamHI and cloned in frame into the corresponding
site in pGAD424, yielding GalAD-AR.N12 (low). The 0.4-kb
EcoRI-Acc651 (blunt ended) fragment from the previously
described pSVAR-123 (8), containing an additional EcoRI site
by addition of an EcoRI linker to the blunt-ended XbaI site,
was cloned in frame into pGAD424 via EcoRI and SmaI
compatible ends, yielding GalAD-AR.N14 (low). GalDBD-
AR.N8 (low) [previously described as pGAL4(DBD)-AR(TAD)
(22)] was digested with RsrII and Acc651, and the blunted
vector was religated, yielding GalDBD-AR.N10 (low). The AR
fragment was excised with BamHI and cloned in frame into
the corresponding site in pGAD424, yielding GalAD-AR.N10
(low). GalAD-AR.N15 (low) was generated by deletion of the
internal PstI fragment from GalAD-AR.N12 (low). GalAD-
AR.N16 (low) was constructed by digesting GalAD-AR.N15
(low) with EcoRI and NcoI, followed by religation of the
blunted vector. GalAD-AR.N13 (low) was prepared by inte-
gration of the 0.5-kb GalAD-AR.N12 (low) PstI fragment into
the homologous GalAD-AR.N16 (low) site. AR.N8, containing
the AR fragment cloned in frame to the SV40 large T antigen
nuclear localization signal in pGAD424, was described pre-
viously as pAR(TAD32494) (22). AR.N12 (low) was generated
by exchanging the Acc651 (blunt ended)-EcoRI fragment of
pGAD424 with the 0.9-kb BamHI (blunt ended)-EcoRI frag-
ment of pTZ19AR.N12. AR.N15 (low) was prepared by di-
gesting GalAD-AR.N15 (low) with Acc651 and BamHI, fol-
lowed by religation of the blunt-ended vector. All high
expression derivatives were constructed by exchanging the
internal HindIII fragments with the internal pACT2 HindIII
fragment. AR.N9 (high) was generated by exchanging the
internal 0.9-kb StuI-EcoRI fragment of AR.N8 (high) with the
0.5-kb StuI-EcoRI fragment of AR.N3 (described above).
AR.N11 (high) was generated by digesting AR.N8 (high) with
NcoI and EcoRI, followed by religation of the blunt-ended
vector. Similarly, the high expression level AR.N10 was gen-
erated by digesting AR.N8 (high) with RsrII and EcoRI, fol-
lowed by religation of the blunt-ended vector. Only the high
expression AR.N constructs were used in the two-hybrid
assays. The expression vectors GalDBD-AR.C (low expres-
sion) and GalAD-AR.C (high expression) were previously de-
scribed as pGAL4(DBD)AR(LBD) and pGAL4(TAD)AR(LBD),
respectively (22). GalDBD-AR.C(EQ) was prepared by inte-
gration of the 0.7-kb StuI-SalI fragment of pSVAR(EQ) (as
described above) into the homologous GalDBD-AR.C sites.
Similarly, the high-expression GalAD-AR.C(EQ) derivative
was generated by integration of the 0.45-kb EcoRI fragment
of pSVAR(EQ) into the homologous GalAD-AR.C site.
CHO Cell Culture, Transfection, and LUC Assay
Chinese hamster ovary (CHO) cells were maintained in
DMEM/F12 culture medium, supplemented with 5% dextran-
coated charcoal-treated FCS (Life Technologies, Gaithers-
burg, MD). For transcription activation experiments, CHO
cells were plated in 12-well plates at a density of 0.6 3 105
cells per well (7 cm2) and grown overnight. Cells were trans-
fected using the calcium phosphate precipitation method as
described previously (36), with AR expression plasmids and
where indicated with TIF2, reporter plasmids (200 ng/well),
and pTZ19 carrier plasmid to a total DNA concentration of 2
mg/well. After an overnight incubation, the cells were washed
and R1881 (methyltrienolone; New England Nuclear, Boston,
MA) or vehicle (0.1% ethanol) was added. After overnight
incubation the cells were harvested for the luciferase (LUC)
assay, as described previously (37). For the GR experiments,
GR.C (50 ng/well) was cotransfected with MMTV-LUC and
pTZ19 carrier plasmid as described above. After overnight
incubation, dexamethasone (10 nM) was added, and lucif-
erase activity was measured the next day. For the coexpres-
sion studies of TIF2 and AR.N1, the total amount of vector,
added to each well, was equalized by the addition of empty
vector, to a total concentration of 800 ng/well. In addition,
pTZ19 carrier plasmid was added to a total concentration of
2 mg DNA/well.
Yeast Growth and Methods
All yeast studies were performed in strain Y190 (MATa, ura3–
52, his3-D200, ade2–101, trp1–901, leu2–3, leu2–112,
GAL4D, GAL80D, URA3::GAL-lacZ, cyhr, LYS2::GAL-HIS3),
which was purchased from CLONTECH. Yeast cells were
grown in the appropriate selective minimal medium [0.67%
(wt/vol) yeast nitrogen base without amino acids and 2%
(wt/vol) dextrose, pH 5.8] supplemented to the nutritional
requirements of the yeast transformants. Yeast transforma-
tions were carried out according to the lithium acetate
method (38).
Quantitative b-GAL activity assays, indicative of AR do-
main interactions, were performed as described previously
(22).
Immunoprecipitation and Immunoblotting
CHO cells were plated in 80-cm2 culture flasks (1 3 106 cells
per flask), grown overnight, and transfected with 4 mg AR-
plasmid and 16 mg pTZ19 as carrier plasmid. The next day,
medium was refreshed and the cells were grown for another
day. Cytosol of the transfected cells was prepared as de-
scribed before (22). Immunoprecipitation was performed as
described previously (39), using monoclonal antibodies
F112.1.1 [directed against synthetic peptide SP197; AR aa
1–20 (40)], F39.4.1 [directed against SP061; aa 301–320;
(41)], or F52.24.4 [directed against SP063; aa 593–612; (39)].
Subsequent to SDS-PAGE and Western blotting, the mem-
brane was blocked with 5% nonfat dry milk and incubated
with polyclonal antisera against SP197, SP061, or SP066
[directed against AR aa 892–910 (40)]. The proteins were
visualized by chemiluminescence detection.
AR proteins in yeast were isolated as described previously
(22). Yeast-lysate samples (2.5 ml) were run on SDS-
polyacrylamide gels, after which the gels were electroblotted
under semidry conditions. The blots were blocked overnight
with 5% nonfat dry milk and incubated with GAL4AD mono-
clonal antibody (CLONTECH) or the polyclonal AR-antibody
SP197. Proteins were visualized by chemiluminescence
detection.
In Vivo Hormone Binding Assay
CHO cells were plated in six-well plates at a density of 1 3
105 cells per well, grown overnight, and transfected as de-
scribed above with AR-C or AR-C(EQ) (0.75 mg/well). The
whole-cell binding assay was performed 48 h later. Cells
were washed once with PBS and incubated with various
[3H]R1881 (New England Nuclear) concentrations (0.01–30
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nM) in the presence or absence of a 200-fold molar excess of
unlabeled R1881 in DMEM/F12 for 1 h at 37 C. The cells were
washed four times with PBS, collected in PBS, and trans-
ferred to a centrifuge tube. After centrifugation (10 min, 800 3
g) the pellet was lysed in 0.5 M NaOH (15 min at 56 C), and
radioactivity was determined by liquid scintillation counting.
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